Medication-Assisted Treatment — Page 2

While long-term methadone maintenance supports sustained recovery for many people, some individuals eventually choose to discontinue methadone. Medically supervised tapering with relapse prevention support optimizes successful discontinuation.

Methadone maintenance is an evidence-based, safe treatment for opioid addiction during pregnancy, significantly improving maternal and fetal outcomes compared to untreated addiction or heroin use. Understanding pregnancy-specific considerations optimizes outcomes.

Methadone is available in multiple formulations including liquid solution, tablets, and wafers. Understanding the advantages and disadvantages of each form helps patients make informed choices about their medication.

While once-daily methadone dosing is standard, certain clinical situations benefit from split dosing where the total daily dose is divided into two smaller doses. Understanding when split dosing is appropriate and its advantages improves treatment outcomes.

Long-acting injectable depot formulations transform addiction treatment by delivering medication over weeks or months from a single injection. This guide covers available options, adherence benefits, and clinical outcomes.

Methadone clinics operate with structured daily schedules designed to ensure medication safety, treatment engagement, and patient stability. Understanding clinic operations and policies before starting treatment reduces anxiety and improves treatment engagement.

Lofexidine offers a non-narcotic alternative for managing opioid withdrawal symptoms, with FDA approval in 2018. This guide covers efficacy, dosing, and patient outcomes.

Sublocade buprenorphine implants provide 6 months of opioid maintenance medication with a single subcutaneous implant. This guide covers efficacy, implantation, and long-term outcomes.

CAM2038 is a monthly subcutaneous buprenorphine injection approved in European markets for opioid maintenance treatment. This guide explores its efficacy, administration, and advantages.

Nalmefene is a selective opioid antagonist approved for alcohol dependence and studied extensively for opioid use disorder. This guide covers mechanisms, efficacy, and clinical applications.

Gabapentin is increasingly used off-label to manage opioid withdrawal symptoms, particularly muscle aches and anxiety. This guide covers efficacy, dosing, and safety considerations.

Topiramate is used off-label to treat substance use disorders co-occurring with mood disorders, anxiety, and impulse control issues. This guide covers efficacy, dosing, and clinical outcomes.

Disulfiram (Antabuse) remains useful in alcohol treatment, but modern understanding focuses on psychological benefit beyond pharmacological deterrence. Updated evidence and integration strategies.

Combining multiple medications in MAT addresses different mechanisms of opioid use disorder. Evidence-based strategies for complex cases and treatment-resistant patients.

Pharmacogenomic testing identifies genetic factors affecting medication metabolism, allowing personalized MAT dosing. This guide covers CYP450 enzymes, testing options, and clinical applications.

An evidence-based clinical guide to Suboxone (buprenorphine/naloxone) treatment for opioid use disorder, covering induction protocols, maintenance therapy, side effects, and long-term recovery outcomes supported by SAMHSA and FDA guidelines.